Coevolution of the hepatitis C virus polyprotein sites in patients on combined pegylated interferon and ribavirin therapy.
Genotype-specific sensitivity of the hepatitis C virus (HCV) to interferon-ribavirin (IFN-RBV) combination therapy and reduced HCV response to IFN-RBV as infection progresses from acute to chronic infection suggest that HCV genetic factors and intrahost HCV evolution play important roles in therapy outcomes. HCV polyprotein sequences (n = 40) from 10 patients with unsustainable response (UR) (breakthrough and relapse) and 10 patients with no response (NR) following therapy were identified through the Virahep-C study. Bayesian networks (BNs) were constructed to relate interrelationships among HCV polymorphic sites to UR/NR outcomes. All models showed an extensive interdependence of HCV sites and strong connections (P ≤ 0.003) to therapy response. Although all HCV proteins contributed to the networks, the topological properties of sites differed among proteins. E2 and NS5A together contributed ∼40% of all sites and ∼62% of all links to the polyprotein BN. The NS5A BN and E2 BN predicted UR/NR outcomes with 85% and 97.5% accuracy, respectively, in 10-fold cross-validation experiments. The NS5A model constructed using physicochemical properties of only five sites was shown to predict the UR/NR outcomes with 83.3% accuracy for 6 UR and 12 NR cases of the HALT-C study. Thus, HCV adaptation to IFN-RBV is a complex trait encoded in the interrelationships among many sites along the entire HCV polyprotein. E2 and NS5A generate broad epistatic connectivity across the HCV polyprotein and essentially shape intrahost HCV evolution toward the IFN-RBV resistance. Both proteins can be used to accurately predict the outcomes of IFN-RBV therapy.
Molecular Epidemiology & Bioinformatics Laboratory, Laboratory Branch, Division of Viral Hepatitis, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA. jlara@cdc.gov
James
J
Lara
Guoliang
G
Xia
Mike
M
Purdy
Yury
Y
Khudyakov
D000220:Adaptation, Biological; D000998:Antiviral Agents / Q000627:therapeutic use*; D024882:Drug Resistance, Viral; D019143:Evolution, Molecular; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000821:virology*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D020815:Polyproteins / Q000235:genetics*; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome
D000998:Antiviral Agents; D020815:Polyproteins; D012254:Ribavirin; D007372:Interferons
Virology. 1997 Apr 14;230(2):217-27
9143277
J Gastroenterol Hepatol. 1999 Oct;14(10):1018-24
10530499
Hepatology. 2005 Sep;42(3):702-10
16108059
Biophys J. 2008 Jun;94(12):4737-50
18339752
Nature. 2005 Aug 18;436(7053):967-72
16107837
J Viral Hepat. 2010 Mar;17(3):208-16
19656286
Proc Natl Acad Sci U S A. 2005 May 3;102(18):6395-400
15851683
Dose Response. 2006 Aug 19;4(2):119-32
18648583
Virology. 2003 Jun 5;310(2):333-42
12781720
Infection. 2005 Feb;33(1):25-9
15750756
Dig Dis Sci. 2001 Oct;46(10):2060-5
11680576
J Virol. 1993 Jul;67(7):3923-30
7685404
J Virol. 2008 Jul;82(13):6644-53
18448540
NIH Consens State Sci Statements. 2002 Jun 10-12;19(3):1-46
14768714
J Virol. 1999 Apr;73(4):2841-53
10074132
Gastroenterology. 2010 Jul;139(1):154-62.e4
20303352
J Gen Virol. 2001 Apr;82(Pt 4):723-733
11257176
Intervirology. 2010;53(1):66-9
20068344
Nat Genet. 2009 Oct;41(10):1100-4
19749758
J Gen Virol. 1998 Jun;79 ( Pt 6):1373-81
9634077
Nature. 2009 Sep 17;461(7262):399-401
19684573
Proteins. 2000 Aug 15;40(3):355-66
10861927
World J Gastroenterol. 2007 May 7;13(17):2416-26
17552024
J Biol Regul Homeost Agents. 2003 Apr-Jun;17(2):153-61
14518715
J Biol Chem. 1998 Jul 10;273(28):17651-9
9651361
Science. 1999 Jul 2;285(5424):107-10
10390359
Gastroenterology. 2003 Jul;125(1):80-8
12851873
J Hepatol. 1997 Jan;26(1):6-13
9148023
J Gen Virol. 1993 Nov;74 ( Pt 11):2391-9
8245854
PLoS Pathog. 2008 Mar 28;4(3):e1000035
18369481
N Engl J Med. 2001 Nov 15;345(20):1452-7
11794193
J Infect Dis. 2000 Jul;182(1):28-35
10882578
J Virol. 2007 Aug;81(16):8752-65
17537855
J Biol Chem. 2001 Dec 7;276(49):46094-8
11602568
Hepatology. 1999 Oct;30(4):1045-53
10498658
J Virol. 1994 Jun;68(6):3631-41
8189501
Virology. 1993 Jul;195(1):297-301
7686313
Hepatology. 2000 Jul;32(1):91-6
10869294
J Infect Dis. 2000 Aug;182(2):397-404
10915068
J Virol. 1998 May;72(5):3691-7
9557650
J Biol Chem. 1982 Jun 25;257(12):6867-70
7085610
Gastroenterology. 2007 May;132(5):1757-66
17484873
J Biol Chem. 2006 Aug 4;281(31):22236-22247
16704979
J Clin Invest. 1995 Jul;96(1):224-30
7542279
FASEB J. 2002 Feb;16(2):185-94
11818366
J Biol Chem. 2003 Oct 24;278(43):41624-30
12913001
Int J Med Sci. 2006;3(2):47-52
16614742
J Virol. 1999 Aug;73(8):6235-44
10400713
Hepatology. 2008 Nov;48(5):1404-11
18846541
Gastroenterology. 1995 Mar;108(3):789-95
7533113
Hepatology. 2005 Oct;42(4):962-73
16149085
Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15394-9
8986822
Hepatology. 2009 Apr;49(4):1335-74
19330875
Gastroenterology. 2010 Nov;139(5):1586-92, 1592.e1
20637200
Hepatology. 1999 Mar;29(3):897-903
10051495
J Med Virol. 2003 May;70(1):62-73
12629645
Clin Liver Dis. 2001 Nov;5(4):895-916
11685800
Bioinformatics. 2005 Feb 1;21(3):413-4
15358614
Ann Intern Med. 2004 Mar 2;140(5):346-55
14996676
Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1200-5
9037030
Lancet. 2001 Sep 22;358(9286):958-65
11583749
J Virol. 2002 Sep;76(17):8505-17
12163570
Science. 2000 Mar 3;287(5458):1555
10733410
J Virol. 2003 May;77(10):5933-47
12719586
J Interferon Cytokine Res. 2004 Jul;24(7):391-402
15296650
Eur J Immunol. 2003 Dec;33(12):3448-57
14635055
J Virol. 1999 Aug;73(8):6490-9
10400744
J Exp Med. 2002 Sep 2;196(5):641-53
12208879
J Viral Hepat. 2008 Mar;15(3):188-99
18233992
J Clin Invest. 2009 Jan;119(1):225-36
19104147
J Virol. 2005 Feb;79(4):2346-55
15681435
J Virol. 2010 Jun;84(11):5751-63
20357091
Cancer Res. 2002 Aug 1;62(15):4406-12
12154047
J Virol. 2008 Aug;82(16):7964-76
18524832
Nature. 2009 Oct 8;461(7265):798-801
19759533
FASEB J. 2003 Mar;17(3):488-90
12551851
Gut. 2004 Sep;53(9):1345-51
15306598
Virus Res. 2009 Apr;141(1):55-62
19185598
Gastroenterology. 2003 May;124(5):1465-75
12730885
J Virol. 2005 Dec;79(24):15417-29
16306613
Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9685-90
18621679
J Viral Hepat. 2000 Jan;7(1):2-14
10718937
Biochim Biophys Acta. 2006 Jun;1758(6):755-63
16777058
J Hepatol. 2000 Nov;33(5):764-72
11097485
Wkly Epidemiol Rec. 1997 Nov 14;72(46):341-4
9385865
J Hepatol. 2005 Oct;43(4):590-8
16237783
J Virol. 1998 Apr;72(4):3060-5
9525629
Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3081-6
11880647
Biochem Soc Trans. 2009 Oct;37(Pt 5):986-90
19754437
J Virol. 2008 Feb;82(4):1665-78
18077728
Hepatology. 1993 Dec;18(6):1293-9
8244252
Hepatology. 2000 Jun;31(6):1360-70
10827164
PLoS One. 2008 May 07;3(5):e2123
18463735
N Engl J Med. 2002 Sep 26;347(13):975-82
12324553
N Engl J Med. 1996 Jan 11;334(2):77-81
8531962
Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3468-72
1314389
Gastroenterology. 2005 Mar;128(3):636-41
15765399
J Virol. 2008 Apr;82(7):3320-8
18216090
J Virol. 1996 Jul;70(7):4438-43
8676467
Br Med Bull. 1990 Apr;46(2):423-41
2116212
J Virol. 2001 Jun;75(12):5703-10
11356980
J Virol. 1994 Aug;68(8):4776-84
7518526
J Viral Hepat. 2007 Feb;14(2):107-15
17244250
PLoS Med. 2009 Dec;6(12):e1000198
20041120
J Biol Chem. 2007 Dec 21;282(51):37158-69
17942391
Nucleic Acids Res. 1994 Nov 11;22(22):4673-80
7984417
J Gen Virol. 2005 Apr;86(Pt 4):1067-1075
15784900
J Hepatol. 1999 Mar;30(3):376-82
10190717
Antiviral Res. 2003 Oct;60(2):103-9
14638405
Hepatology. 2007 Nov;46(5):1548-63
17929300
Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13318-23
11078521
World J Gastroenterol. 2007 Feb 28;13(8):1195-203
17451199
EMBO J. 2000 Feb 15;19(4):729-40
10675342
Semin Liver Dis. 2005 Feb;25(1):93-104
15732001
J Infect Dis. 2002 Mar 1;185(5):573-83
11865413
Gastroenterology. 2006 Aug;131(2):470-7
16890601